haloperidol has been researched along with Dyslipidemia in 2 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Hamer, RM | 1 |
| Dunlop, BW | 1 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Ramirez-Bonilla, ML | 1 |
| Gonzalez-Blanch, C | 1 |
| Martinez-Garcia, O | 1 |
| Vazquez-Barquero, JL | 1 |
1 trial available for haloperidol and Dyslipidemia
| Article | Year |
|---|---|
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
1 other study available for haloperidol and Dyslipidemia
| Article | Year |
|---|---|
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Fema | 2009 |